|Bid||0.00 x 1800|
|Ask||0.00 x 900|
|Day's Range||31.00 - 31.92|
|52 Week Range||11.56 - 36.84|
|Beta (3Y Monthly)||1.14|
|PE Ratio (TTM)||10.33|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.18|
Copenhagen, December 11, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), announces that its Articles of Association have been amended to reflect the recent grant of warrants to the Company’s Executive Management and Corporate Management, as announced in Company Announcement no. 42 / 2019 on December 5, 2019. The warrant program is an incentive scheme reflecting Zealand’s objective to attract and retain first-rate employees and help ensure shared short- and long-term interests for the management, employees and shareholders of the Company.
Company announcement – No. 45 / 2019 Financial calendar for Zealand Pharma in 2020 Copenhagen, December 10, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR No..
Company announcement – No. 44 / 2019 Zealand Pharma partner Beta Bionics receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System The iLet is a.
Company announcement – No. 43 / 2019 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely.
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78) announces the granting of warrants to employees and the CFO. The warrants are granted under the warrant program covered by the authority pursuant to Section 8.4 of Zealand’s Articles of Association, adopted at Zealand’s General Meeting on April 21, 2015. A total of 48,915 warrants have been granted, giving the rights to subscribe for up to 48,915 new Zealand shares with a nominal value of DKK 1 each, corresponding to 0.14% of Zealand's total outstanding share capital.
Zealand Pharma A/S ("Zealand") (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the second Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with congenital hyperinsulinism (CHI) has been initiated. This Phase 3 trial will enroll up to 12 CHI children from the ages of 7 days to 1 year who are dependent upon intravenous glucose infusions to maintain their plasma glucose levels.
Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital. In Company announcement No. 39/2019, Zealand announced an increase in share capital relating to the exercise of employee warrants.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Company announcement – No. 40 / 2019 Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program.
Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 158,225 divided into 158,225 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand's employee warrant programs.
Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR No. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of next generation peptide medicines, today announced financial results through the third quarter of 2019.
MORRISVILLE, N.C., Nov. 12, 2019 -- Syneos Health® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a.
Press Release – No. 20 / 2019 Zealand Pharma hosts conference call on November 14 at 4 PM CET (10 AM ET) to present third quarter results for 2019 Copenhagen, October 28,.
The transaction strengthens the leadership of Zealand Pharma (ZEAL.CO) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Zealand Pharma also gains access to a unique screening library of some 5,000 peptide macrocycles with potential in multiple therapeutic areas. The agreement provides for a total potential deal value of up to US $80 million, with a series of contingent value rights tied to future development, regulatory and commercial milestones.
Company announcement – No. 36 / 2019 Total number of shares and voting rights in Zealand Pharma at September 30, 2019 Copenhagen, September 30, 2019 – Zealand Pharma A/S.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Celgene ...
Zealand Pharma A/S (“Zealand”) (ZEAL.CO), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes. Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand.
With reference to the company announcement no. 30/2019 dated September 5, 2019 regarding a private placement and directed issue of 3,975,000 new ordinary shares of the company (the "New Shares"), Zealand Pharma A/S ("Zealand") announces that it has today increased its share capital by DKK 3,975,000, divided into 3,975,000 New Shares with a nominal value of DKK 1 each. Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 35,806,290 divided into 35,806,290 shares with a nominal value of DKK 1 each.
In reference to Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78) company announcement 30/2019 published September 5, 2019, a total of 3,975,000 shares were due to be issued to Van Herk Investments B.V. and registered with the Danish Business Authority on September 10, 2019. For technical reasons, the registration of the shares with the Danish Business Authority is expected to take place on September 11, 2019 and admission for trading is now expected to take place not later than September 13, 2019. No announcements or information regarding the Placement may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose.
Company announcement – No. 31 / 2019 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”).